Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
6796 | 1366 | 26.1 | 65% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | IMMUNOFIXATION ELECTROPHORESIS | Author keyword | 35 | 73% | 2% | 27 |
2 | FREE LIGHT CHAINS | Author keyword | 19 | 48% | 2% | 30 |
3 | SERUM FREE LIGHT CHAINS | Author keyword | 19 | 64% | 1% | 18 |
4 | MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE | Author keyword | 16 | 29% | 3% | 47 |
5 | IMMUNOFIXATION | Author keyword | 15 | 38% | 2% | 32 |
6 | SERUM PROTEIN ELECTROPHORESIS | Author keyword | 15 | 41% | 2% | 29 |
7 | MONOCLONAL GAMMOPATHY | Author keyword | 15 | 16% | 6% | 88 |
8 | MGUS | Author keyword | 15 | 26% | 4% | 49 |
9 | SERUM FREE LIGHT CHAIN | Author keyword | 12 | 75% | 1% | 9 |
10 | URINE PROTEIN ELECTROPHORESIS | Author keyword | 11 | 100% | 0% | 6 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | SIGNIFICANCE MGUS | 42 | 74% | 2% | 31 |
2 | MONOCLONAL GAMMOPATHIES | 35 | 28% | 8% | 108 |
3 | IMMUNOFIXATION | 32 | 54% | 3% | 42 |
4 | GAMMOPATHIES | 27 | 53% | 3% | 36 |
5 | UNDETERMINED SIGNIFICANCE MGUS | 26 | 42% | 4% | 48 |
6 | LIGHT CHAIN RATIO | 23 | 57% | 2% | 27 |
7 | SMOLDERING MULTIPLE MYELOMA | 23 | 51% | 2% | 32 |
8 | IMMUNOFIXATION ELECTROPHORESIS | 17 | 68% | 1% | 15 |
9 | PARAPROTEINS | 15 | 59% | 1% | 17 |
10 | BENCE JONES PROTEINURIA | 14 | 59% | 1% | 16 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
---|---|---|---|---|
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management | 2010 | 170 | 21 | 86% |
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders | 2009 | 237 | 34 | 74% |
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma | 2008 | 110 | 20 | 80% |
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma | 2014 | 13 | 87 | 49% |
Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites | 2012 | 17 | 43 | 77% |
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies | 2011 | 49 | 50 | 44% |
Dilemmas in Treating Smoldering Multiple Myeloma | 2015 | 1 | 67 | 33% |
Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics | 2012 | 13 | 46 | 61% |
Immunoglobulin Heavy Chain/Light Chain Pairs (Hlc, Hevylite (TM)) Assays for Diagnosing and Monitoring Monoclonal Gammopathies | 2014 | 2 | 7 | 86% |
Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis | 2009 | 63 | 44 | 64% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | JOSE CARRERAS IMMUNO GENE THER Y | 6 | 53% | 0.6% | 8 |
2 | MULTIPLE MYELOMA SECT | 6 | 35% | 1.0% | 14 |
3 | QEMC | 1 | 50% | 0.1% | 2 |
4 | BIOCHEMBIOTECHNOL S | 1 | 50% | 0.1% | 1 |
5 | BIOCHIM D | 1 | 50% | 0.1% | 1 |
6 | BIOMED UNIT LIVER DIS | 1 | 50% | 0.1% | 1 |
7 | BMT PROGRAM BC | 1 | 50% | 0.1% | 1 |
8 | CORNELL MED PATHOL | 1 | 50% | 0.1% | 1 |
9 | CYTOL ANALYT MED ROCKEFELLER | 1 | 50% | 0.1% | 1 |
10 | EMATOL UNIV | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000190680 | MU HEAVY CHAIN DISEASE//HEAVY CHAIN DISEASE//GAMMA HEAVY CHAIN DISEASE |
2 | 0.0000145563 | LIGHT CHAIN DEPOSITION DISEASE//CRYSTAL STORING HISTIOCYTOSIS//HEAVY CHAIN DEPOSITION DISEASE |
3 | 0.0000136165 | PLASMA CELL LEUKEMIA//PRIMARY PLASMA CELL LEUKEMIA//MMSET |
4 | 0.0000127558 | WALDENSTROMS MACROGLOBULINEMIA//WALDENSTROM MACROGLOBULINEMIA//BING WALDENSTROMS MACROGLOBULINEMIA |
5 | 0.0000104823 | MULTIPLE MYELOMA//LENALIDOMIDE//BORTEZOMIB |
6 | 0.0000103131 | MOTT CELL//RUSSELL BODIES//MOTT CELLS |
7 | 0.0000098200 | PLANT FOOD SUPPLEMENT//FLUOROIMMUNOSENSING//MED PENN HOSP |
8 | 0.0000082126 | PSEUDOHYPERPHOSPHATEMIA//CATAPPA//FERENE S |
9 | 0.0000075044 | IGD MYELOMA//IGD RECEPTOR//IMMUNOGLOBULIN D |
10 | 0.0000063379 | MYELOMA BONE DISEASE//CAM DR//HEIM |